Naltrexone Alcohol Drug Rehab Assisted Recovery Midwest
Naltrexone Alcohol Drug Rehab Assisted Recovery Midwest – Naltrexone Breaks the Cycle of Addiction New hope for alcohol dependence and opiate drug addiction. Naltrexone is one of the first anti-craving medications approved by the US Food and Drug Administration (FDA) for use in the treatment of alcoholism and opiate addiction. Naltrexone comes in two forms: 1) Vivirol®-an injectable time released form of naltrexone that is taken once a month. Click to visit Vivitrol’s website for more information. 2) ReVia© or naltrexone- taken daily in pill form. Here are some of the many benefits of naltrexone in the treatment of drug and alcohol dependence: • Most patients experience dramatic reductions in craving within hours of taking the first dose. • Naltrexone blocks the high of alcohol and narcotics, reducing the incentive to drink or use drugs and significantly increasing treatment success. • Naltrexone is a non-habit forming medication that can be discontinued at any time. • Naltrexone can be given with other medications, especially those used to treat depression and other such psychiatric conditions. • Naltrexone works best when used in combination with relapse-prevention therapies. Call Assisted Recovery’s 24-Hour Help Line (314) 645-6840 for a free, confidential consultation.
Heroin addiction growing
Filed under: drug addiction help line
… is hardly a recreational drug. “It's not like doing a line of cocaine — if you're an addict, you must have it,” he said. … Oglesby, formerly the top drug prosecutor in Wicomico County, called drug abuse “one of the major problems in our …
Read more on Delmarva Now
Catalyst Pharmaceutical Partners Updates Guidance on Timing of Top-Line Data …
Filed under: drug addiction help line
Catalyst licensed CPP-109 from Brookhaven National Laboratory for the treatment of cocaine and other addictions, and has been granted "Fast Track" status by the U.S. Food and Drug Administration (FDA) for cocaine addiction. Under the Federal Food, Drug …
Read more on NASDAQ